When Gilead Sciences (Nasdaq: GILD) presents its annual results on Monday, there will be a few eyes on the latest sales of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), a drug that won US approval a year ago to treat HIV-1 infection in treatment-naïve adults.
European approval followed in the summer and Biktarvy quickly became the company’s lead growth driver.
In the third quarter of 2018, the product’s sales had already reached $386 million, and analysts have predicted that peak annual sales could be between $5 billion and $10 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze